netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Formulary Chapter 5: Infections - Full Section
Notes:

This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net

Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.

Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns.

 Useful Links
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
spacespace Table 1. Summary of antibacterial therapy (0,0)
spacespace Table 2. Summary of antibacterial prophylaxis (0,0)
05.01.01 Penicillins (0,0)
05.01.01.01 Benzylpenicillin and phenoxymethylpenicillin (2,0)
05.01.01.02 Penicillinase-resistant penicillins (3,0)
05.01.01.03 Broad-spectrum penicillins (4,0)
05.01.01.04 Antipseudomonal penicillins (1,0)
05.01.01.05 Mecillinams (1,0)
05.01.02.01 Cephalosporins (12,0)
05.01.02.02 Carbapenems (3,0)
05.01.03 Tetracyclines (9,0)
05.01.04 Aminoglycosides (4,0)
05.01.05 Macrolides (5,0)
05.01.06 Clindamycin (2,0)
spacespace Chloramphenicol (1,0)
spacespace Fosfomycin (2,0)
spacespace Fusidic acid (2,0)
spacespace Glycopeptide antibacterials (5,0)
spacespace Linezolid (2,0)
spacespace Polymyxins (2,0)
spacespace Rifaximin (2,0)
spacespace Fidaxomicin (1,0)
05.01.08 Sulphonamides and trimethoprim (3,0)
05.01.09 Antituberculosis drugs (14,0)
05.01.10 Antileprotic drugs (1,0)
05.01.11 Metronidazole and tinidazole (2,0)
05.01.12 Quinolones (5,0)
05.01.13 Urinary-tract infections (2,0)
05.02 Antifungal drugs (11,0)
spacespace Treatment of fungal infections (0,0)
05.02.01 Triazole antifungals (0,0)
05.02.02 Imidazole antifungals (0,0)
05.02.03 Polyene antifungals (0,0)
05.02.04 Echinocandin antifungals (2,0)
05.03 Antiviral drugs (6,0)
05.03.01 HIV infection (4,0)
spacespace HIV-integrase inhibitors (4,0)
spacespace Nucleoside reverse transcriptase inhibitors (12,0)
spacespace Protease inhibitors (4,0)
spacespace Non-nucleoside reverse transcriptase inhibitors (4,0)
spacespace Other antiretrovirals (8,0)
05.03.02.01 Herpes simplex and varicella-zoster infection (2,0)
05.03.02.02 Cytomegalovirus infection (6,0)
05.03.03 Viral hepatitis (5,0)
05.03.03.01 Chronic hepatitis B (0,0)
05.03.03.02 Chronic hepatitis C (7,0)
05.03.04 Influenza (3,0)
05.03.05 Respiratory syncytial virus (2,0)
05.04 Antiprotozoal drugs (0,0)
05.04.01 Antimalarials (7,0)
spacespace Treatment of malaria (0,0)
spacespace Falciparum malaria (treatment) (0,0)
spacespace Benign malarias (treatment) (0,0)
spacespace Prophylaxis against malaria (0,0)
spacespace Specific recommendations (0,0)
spacespace Artemether with lumefabtrine (0,0)
spacespace Primaquine (0,0)
05.04.02 Amoebicides (2,0)
05.04.03 Trichomonacides (2,0)
05.04.04 Antigiardial drugs (3,0)
05.04.06 Trypanocides (0,0)
05.04.08 Drugs for pneumocystis pneumonia (1,0)
spacespace Treatment (0,0)
spacespace Prophylaxis (0,0)
05.05 Anthelmintics (2,0)
05.05.01 Drugs for threadworms (1,0)
05.05.02 Ascaricides (0,0)
spacespace Taenicides (0,0)
spacespace Hydatid disease (0,0)
05.05.04 Drugs for hookworms (0,0)
05.05.06 Filaricides (0,0)
05.05.08 Drugs for strongyloidiasis (0,0)
netFormulary